Targeting the inactive conformation of protein kinases: computational screening based on ligand conformation

Recent strategies to develop potent and selective inhibitors of protein kinases have targeted a pocket exposed by many kinases in their inactive conformation. In order to identify these Type II kinase inhibitors, we have developed a computational screen using combined pharmacophore- and shape-based criteria. Here, we successfully discriminate Type II kinase inhibitors from a large number of Type I and other decoy ligands taken from the MOE kinase and DUD databases. The pharmacophore component of the screen is effective in limiting false positives, whilst ROCS rapidly prioritizes Type II kinase inhibitors for this analysis. Here we also show that the screen does not appear strongly biased towards particular kinase target types, and can detect Type IIs of diverse linker chemistry. Analysis of this large scale validation not only identifies known Type II kinase inhibitors but additionally identifies DUD compounds with relatively low scaffold similarity to known Type II kinase inhibitors but high similarity in 3D conformation. Our method therefore uses 3D structure to detect putative active compounds which would not have been detected by a 2D-only approach. The method therefore shows promise as a tool in the discovery of inhibitors with potentially novel scaffolds that target protein kinases in their inactive conformational state.

[1]  Malcolm J. McGregor,et al.  A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors , 2007, J. Chem. Inf. Model..

[2]  Ji-Xia Ren,et al.  Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. , 2009, Journal of molecular graphics & modelling.

[3]  G. Müller,et al.  Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition , 2008, Expert opinion on drug discovery.

[4]  Konstantin V Balakin,et al.  VEGF/VEGFR signalling as a target for inhibiting angiogenesis , 2007, Expert opinion on investigational drugs.

[5]  Daniel Rauh,et al.  A new screening assay for allosteric inhibitors of cSrc. , 2009, Nature chemical biology.

[6]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[7]  Richard Kendall,et al.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.

[8]  P. Bohlen,et al.  Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. , 2009, Bioorganic & medicinal chemistry.

[9]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[10]  Pascal Bonnet,et al.  Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors , 2011, J. Comput. Aided Mol. Des..

[11]  Taebo Sim,et al.  A general strategy for creating "inactive-conformation" abl inhibitors. , 2006, Chemistry & biology.

[12]  A. Kiselyov,et al.  Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. , 2005, Bioorganic & medicinal chemistry letters.

[13]  Ping Chen,et al.  2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase in , 2006, Journal of medicinal chemistry.

[14]  Scott P. Brown,et al.  A unified, probabilistic framework for structure- and ligand-based virtual screening. , 2011, Journal of medicinal chemistry.

[15]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.